Matsuoka H, et al. - Researchers examined duloxetine for its efficacy in cancer-related neuropathic pain (CNP) nonresponsive or intolerant to opioid-pregabalin combination therapy via conducting a multicenter, randomized, double-blind, placebo-controlled trial at 12 specialized palliative care services in Japan. They allocated 70 patients with CNP average pain scores [Brief Pain Inventory-item 5] ≥ 4 in the previous 24 h to either the duloxetine group (group D; this group was administered duloxetine 20 mg/d titrated to 40 mg/d) or the placebo group (group P; this group was administered placebo). Group D vs group P had clinically meaningful pain improvement (≥ 30%) in 44.1% (n = 15) vs 18.2% (n = 6) of patients, respectively; 32.4% (n = 11) vs 3.0% (n = 1) of patients in groups D and P, respectively, reported pain reduction ≥ 50%. Findings suggest that refractory CNP could be alleviated via adding duloxetine to opioid- pregabalin therapy.